India and England will play four tests, five Twenty20 matches and three one-dayers in February-March in India with the high-profile series restricted to just three venues due to the COVID-19 pandemic, both cricket boards said on Thursday.
The series will kick off on February 5th with Chennai hosting the opening two tests before the sides head to the Western Indian city of Ahmedabad to play the first international match at the world's largest cricket stadium.
The Motera stadium, with a capacity of 110,000, has displaced the Melbourne Cricket Ground as the world's largest cricket stadium, and was inaugurated by U.S. President Donald Trump during his visit to India in February.
The refurbished stadium will host the final two tests with the third to be played with pink balls under lights.
Motera will also hold the five T20 internationals, which will work as warm-ups for both sides ahead of the World Twenty20 later in the year in India.
"The prospect of becoming the first international side to play at the magnificent Sardar Patel Stadium in Ahmedabad adds an extra dimension to the tour and I know will be something that is a highlight for both the players and management," said Tom Harrison, the chief executive of England's cricket board.
Pune, situated about 150 kilometres from Mumbai, will host the final leg of the series consisting of three 50-over matches.
England will arrive in Chennai directly from Colombo on Jan. 27 after playing two test matches in Sri Lanka.
The series will be India's first at home since South Africa's tour in March was called off midway through due to the pandemic.
The United Arab Emirates hosted the 2020 edition of the popular Indian Premier League due to the situation with the coronavirus in India, which has seen 9.77 million infections, the second-highest in the world after the United States, with a death toll nearing 142,000.
"The BCCI prioritises health and safety of both teams and will leave no stone unturned to make sure that the tour is held adhering to all safety protocols agreed by the BCCI and ECB medical teams," BCCI secretary Jay Shah said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.